The association of plasminogen activator inhibitor-1 level with ischemic stroke (preliminary study)
Aim Recently, increased plasminogen activator inhibitor-1 (PAI-1) has been known a risk factor for ischemic heart disease. However, the association of increased PAI-1 level with ischemic stroke remains unclear. The aim of this study was to analyze the association of PAI-1 level with ischemic stroke.
Methods By case control design we involved 38 ischemic stroke and 38 risky-matched control subjects who fulfilled the criteria. The PAI-1 level was determined by ELISA method using Asserachrom PAI-1 from Stago.
Results High PAI-1 level was found more frequent in ischemic stroke subjects than in control subjects (21.1% vs. 7.9 % with OR 3.1; 95 % CI 0.757 - 12.790). The analysis of all studied subjects showed that there was a weak negative correlation between PAI-1 level and age (r = -0.4; P = 0.000). High PAI-1 level was found more frequent in younger (40 - 58 years old) than in the older subjects (60 - 84 years old) (20% vs. 9.8 %) (p=0.004).
Conclusion The result of this preliminary study suggested an association between PAI-1 level and ischemic stroke in younger age. Further study with larger subjects is recommended to confirm this association. (Med J Indones 2009;19:158-63)
Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. The Lancet. 2002;1:149-56.
Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice Vol 1. 4thed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 355-65.
Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis (the ARIC study). Circulation. 1995;91:284-90.
Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic risk factors in arterial thrombosis. Thrombosis and Haemostasis. 2001;86:374-85.
Sakata T, Mannami T, Baba S, et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with intimal-medial thickness of carotid arteries. Atherosclerosis. 2004;176:355-60.
Cortellaro M, Cofrancesco E, Boschetti C; et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients, a case control study. Arteriosclerosis and Thrombosis 1993;13:1412-7.
Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson B. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996;27:1066-71.
Vaughan D. Angiotensin and vascular fibrinolytic balance. American Journal Hypertension. 2002;15:3S-8S.
Margaglione M, Cappucci G, Addedda M; et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to enviromental and genetic determinants. Arteriosclerosis, Thrombosis and Vascular Biology. 1998;18:562-67.
Kohler H, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N England J Med. 2000;342:1792-801.
Binder BR, Christ G, Grubber F, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci. 2002; 17: 56-61.
Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995; 91: 764-70.
Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive effect PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arteriosclerosis, Thrombosis and Vascular Biology. 2001;21:1071-7.
De Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. British Heart Journal. 1994;71:504-7.
Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thrombosis and Haemostasis. 1995; 74: 71-6.
Copyright (c) 2010 Yenny Surjawan, Rahajuningsih D. Setiabudy, Marzuki Suryaatmadja, Teguh A.S. Ranakusuma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.